Unfortunately due to unforeseen circumstances Prof Shinya Yamanaka had to withdraw his participation at TERMIS-EU 2017.
Tentative title: Strengthening the health system while responding to a health crisis: lessons learned from Sierra Leone and Rwanda
Corrado Cancedda MD, PhD, Partners In Health, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA.
Corrado Cancedda, MD, PhD was trained in Internal Medicine and Infectious Disease. He is an Associate Physician at Brigham and Women's Hospital in the Division of Global Health Equity and practicing clinician within the Department of Medicine, and he is an Instructor and teacher of Global Health Delivery within the Department of Global Health and Social Medicine at Harvard Medical School. Dr. Cancedda has extensive expertise in curriculum development, global medical education, and academic partnerships. He worked four years in Rwanda as Chief of Medical Education and Director of the Department of Medical Education and Training for Partners In Health. During his tenure, Dr. Cancedda successfully lead the development and implementation of educational and in-service training programs aimed at Rwandan health professionals and leveraged the educational resources available at Harvard Medical School and Brigham and Women’s Hospital to improve the quality and increase the scope and diversity of such trainings. Working under the leadership of the Ministry of Health and in partnership with the Clinton Health Access Initiative, Dr. Cancedda contributed to the conceptualization, development, launch, and implementation of the Rwanda Human Resources for Health (HRH) Program. Lead by the MOH and supported by the United States Government, this ambitious initiative seeks to build the country’s health education infrastructure through the contributions of top North American universities and academic medical centers (AMCs) within a timeframe spanning from 2012 to 2018. These institutions will supply full-time specialist faculty and collaborate with each other and their Rwandan counterparts on all aspects of health professional education. Dr. Cancedda is the principal investigator for the contribution of Harvard Medical School and Harvard-affiliated hospitals to the Rwanda HRH Program. Dr. Cancedda’s interest lies in the establishment of mutually beneficial academic partnerships between universities and AMCs from the resource-rich world and from developing countries as a mean to address shared global health challenges and promote global health equity.
Title: The role of tissue-specific stem/progenitors cells in tissue engineering and regenerative medicine
Dr. Pamela Gehron Robey, Senior Investigator, Skeletal Biology Section, National Institute of Dental and Craniofacial Diseases; previous Co-Coordinator, NIH Bone Marrow Stromal Cell Transplantation Center; Acting Scientific Director, NIH Stem Cell Unit.
Prof. Robey's research group has a long-term interest in defining the biological properties of post-natal skeletal stem cells (SSCs) and how they are altered in genetic and acquired diseases, and with the major goal to further develop techniques for bone regeneration in human patients with skeletal defects
Her work has led to following the clinical studies and trials:
- Evaluation and treatment of skeletal diseases
- Collection of bone marrow from healthy volunteers and patients for the production of clinical bone marrow stromal cell (BMSC) products.
- Development of a Drug Master File and INDs for use by other clinical investigators at the NIH
- Currently developing a clinical trial for regeneration of jawbone lost due to removal of benign tumors
Title: From Conception to the Clinic, Making Ideas Useful
Professor Jeffrey M Karp, Brigham & Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Boston, USA.
Prof. Jeff Karp is a world leader in drug delivery, stem cell therapeutics, and tissue adhesives. He is an Associate Professor at Brigham and Women’s Hospital, Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and an affiliate faculty at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology.
He has published >100 peer-reviewed papers (>10,500 citations) and has given 220 national and international invited lectures and has 65 issued or pending patents. Several of his technologies have formed the foundation for products on the market or under development and for the launch of companies including: Gecko Biomedical, Skintifique, Frequency Therapeutics, and Alivio Therapeutics.
The Boston Business Journal recognized Prof. Karp as a Champion in Healthcare Innovation and MIT’s Technology Review Magazine (TR35) recognized him as being one of the top innovators in the world (3 members from his laboratory have received this award). His work has been selected by Popular Mechanic’s “Top 20 New Biotech Breakthroughs that Will Change Medicine.” He gave a TEDMED talk on bioinspired medical innovation and is a member of the TEDMED Editorial Advisory Board. In 2015 he received a Breakthrough Award from the Kenneth Rainin Foundation and was a commencement speaker at the University of Toronto.
Prof. Karp was selected as the Outstanding Faculty Undergraduate Mentor among all Faculty at MIT and he received the HST McMahon Mentoring award for being the top mentor of Harvard-MIT students. To date, 18 trainees from his laboratory have secured faculty positions and many others impactful positions in pharma and biotech industries.
Title: Enhanced imaging techniques and their role in regenerative medicine
Katja Schenke-Layland, Professor of Medical Technologies and Regenerative Medicine, Department for Women's Health at the University Women's Hospital, Tubingen, Germany. Interim Director of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB) and Department Head of the Department of Cell and Tissue Engineering. Adjunct Associate Professor, Department of Medicine/Cardiology, the University of California in Los Angeles (UCLA). Executive Editor of Advanced Drug Delivery Reviews (Elsevier).
The Schenke-Layland Lab focuses on the translation of human development into clinically relevant biomaterials and regenerative therapies, and the development of diagnostic tools to assess (stem) cell states, discover therapeutic candidates and diagnose diseases. She began her interdisciplinary work in the non-invasive imaging of tissues, cells and extracellular matrix (ECM) at the University of Jena, Germany where she helped develop new methods using multiphoton laser-based confocal microscopy and second harmonic generation (SHG) to analyze the damaging effects of decellularization and cryopreservation on cardiac tissues. She later employed these technologies to monitor ECM states in cartilage as well as cardiovascular and endocrine tissues. Katja has also partnered with major multinational corporations to incorporate non-invasive methodologies into their product development cycles. She has since focused on the use of Fluorescence Lifetime Imaging Microscopy (FLIM) and Raman microspectroscopy as marker-free optical methods to determine cell and tissue developmental states and qualities. She is also investigating the potential of femtosecond lasers for the optotransfection of cells and the real-time monitoring of 3D cell and tissue cultures. Katja was recently named one of Germany's Top 100 innovators by the Handelsblatt financial magazine for her focus on natural, cell-free tissue engineering and won the 2014 TERMIS-EU Young Investigator Award. She will soon co-found a new spinoff that will exploit a technology that she developed in the area of myocardial infarction and was a finalist with her co-founders in the 2016 CyberOne business plan competition.